ANTIBODY DEVELOPMENT
MONOCLONAL ANTIBODIES
At OBT, we collaborate with world leaders in the field to develop antibodies specific to the unique cancer targets identified by us. The monoclonal antibodies incorporated into our antibody-drug conjugates (ADCs) are engineered to bind specifically to highly expressed proteins on the cancer cell membranes and selected specifically for optimum performance in delivering toxins to cancer cells.
BISPECIFIC ANTIBODIES
A bispecific antibody is one that can bind simultaneously to two different antigens. With our unique matrix of cancer-immune cell target combinations, OBT is uniquely positioned to develop bispecific molecules to enhance recruitment and activation of immune cells for the targeted killing of cancer cells.
At OBT, we collaborate with world leaders in the field to develop antibodies specific to the unique cancer targets identified by us. The monoclonal antibodies incorporated into our antibody-drug conjugates (ADCs) are engineered to bind specifically to highly expressed proteins on the cancer cell membranes and selected specifically for optimum performance in delivering toxins to cancer cells.
BISPECIFIC ANTIBODIES
A bispecific antibody is one that can bind simultaneously to two different antigens. With our unique matrix of cancer-immune cell target combinations, OBT is uniquely positioned to develop bispecific molecules to enhance recruitment and activation of immune cells for the targeted killing of cancer cells.
Therapies stemming from the combination of OBT's IO matrix of target combinations and bispecific antibodies harness the body's immune system to kill cancer cells. This results in a highly specific IO response in the absence of the systemic side effects encountered with conventional chemotherapies.
ANTIBODY SCREENING
3D TUMOUR-EXPLANT MODEL
OBT’s 3D explant model allows ex-vivo culture of patient-derived fresh tumour samples. This unique setup maintains the tumour microenvironment and provides a powerful tool for:
OBT’s 3D explant model allows ex-vivo culture of patient-derived fresh tumour samples. This unique setup maintains the tumour microenvironment and provides a powerful tool for:
- Screening of therapies for activity in tumour microenvironment
- Analysis of the phenotype and functional properties of tumour-infiltrating lymphocytes (TILs)
- Benchmarking OBT’s therapeutic candidates against current therapies
- Testing of synergistic activity with other therapies
- Exploiting inter-patient variability for biomarker identification
3D explant culture allows rapid screening of therapeutic molecules.
Such an early and focused screen accelerates the selection of most active lead development compound for in-depth preclinical studies. Furthermore, testing therapies in patient-derived tumour samples provides data on functional activity in a human setting and complements animal models which are not always informative for IO therapies."
